Filter Results:
(1,246)
Show Results For
- All HBS Web
(1,246)
- People (5)
- News (171)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (758)
Show Results For
- All HBS Web
(1,246)
- People (5)
- News (171)
- Research (929)
- Events (6)
- Multimedia (12)
- Faculty Publications (758)
- September 1997
- Case
Bayer AG (B)
By: John A. Quelch
Bayer's senior executives detail the communications challenge program that resulted from the company's reacquisition of its brand name and trademark cross, which gave Bayer one name worldwide for the first time since World War I. View Details
Keywords: Globalized Firms and Management; War; Acquisition; Trademarks; Brands and Branding; Communication Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Germany
Quelch, John A., and Robin Root. "Bayer AG (B)." Harvard Business School Case 598-032, September 1997.
- 2000
- Chapter
In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals
By: Gary P. Pisano
Keywords: Competency and Skills; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry
Pisano, Gary P. "In Search of Dynamic Capabilities: The Origins of R&D Competence in Biopharmaceuticals." Chap. 5 in The Nature and Dynamics of Organizational Capabilities, edited by Giovanni Dosi, Richard Nelson, and Sidney Winter, 129–154. New York: Oxford University Press, 2000.
- 01 Sep 2015
- Blog Post
Building a Startup at HBS
prototype which we showcased at HBS and tested out in the NICU to observe its efficacy and nurse uptake. While we each embarked on different paths after the end of first year– from launching a new healthcare venture in Africa, to working at large View Details
- Fast Answer
Transforming Health Care Delivery
Books Books and journal titles on all aspects of the health care, life sciences and pharmaceutical sectors View Details
- 28 Apr 2009
- First Look
First Look: April 28, 2009
tilted towards old age than annuities. Several advantages of this are discussed, including some that may explain why tontines have proven popular with consumers in the past. Download the paper: http://www.hbs.edu/research/pdf/09-121.pdf PublicationsWhere Is the... View Details
Keywords: Martha Lagace
- 28 Oct 2014
- First Look
First Look: October 28
Business School Case 515-007 Pfizer and AstraZeneca: Marketing an Acquisition (A) In 2014, Pfizer proposed a friendly acquisition of AstraZeneca, but the AstraZeneca board resisted over price and strategy concerns. Was this good for View Details
Keywords: Carmen Nobel
- Web
Lessons from History - Creating Emerging Markets
watched a short video of Yusuf Hamied discussing the necessity of incremental innovation in the pharmaceuticals industry in the 2000s. Lively discussion then ensued, moderated by HBS Professors Tarun Khanna, Srikant Datar, and Geoffrey... View Details
- 27 Aug 2019
- News
A Shot at Success
says Feickert of the Seattle Seahawks quarterback. “But most people don’t know his older brother, Harrison, was also a standout Division I football player who has had a very successful career as an entrepreneur and in the pharmaceutical... View Details
Keywords: April White
- January 2024
- Supplement
Accounting Red Flags or Red Herrings at Catalent? (B)
By: Joseph Pacelli, ZeSean Ali and Tom Quinn
GlassHouse Research identified accounting red flags at Catalent. Fiat Lux Partners countered most of GlassHouse’s claims. Who was right? This update explores the aftermath of the short seller duel. View Details
Keywords: Accounting Audits; Acquisition; Budgets and Budgeting; Business Earnings; Earnings Management; Cost Accounting; Fair Value Accounting; Financial Reporting; Revenue Recognition; Integrated Corporate Reporting; Fairness; Moral Sensibility; Values and Beliefs; Government Legislation; Conflict of Interests; Announcements; Blogs; Debates; Lawsuits and Litigation; Stocks; Performance Productivity; Pharmaceutical Industry; Pharmaceutical Industry; United States
Pacelli, Joseph, ZeSean Ali, and Tom Quinn. "Accounting Red Flags or Red Herrings at Catalent? (B)." Harvard Business School Supplement 124-055, January 2024.
- March 2023
- Case
Moderna
By: Marco Iansiti, Karim R. Lakhani, Hannah Mayer, Kerry Herman, Allison J. Wigen and Dave Habeeb
This multimedia case follows the story of Moderna and its entry into vaccine development in the wake of the COVID-19 pandemic. In summer 2020, Stephane Bancel, CEO of biotech firm Moderna, faces several challenges as his company races to develop a vaccine for COVID-19.... View Details
- March 2022
- Teaching Note
Digital Manufacturing at Amgen
By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
This teaching note provides guidance for instructors teaching “Digital Manufacturing at Amgen,” case no. 621-008. View Details
Keywords: Change; Change Management; Decision Making; Cost vs Benefits; Decisions; Information Technology; Analytics and Data Science; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Jobs and Positions; Knowledge; Leadership; Organizational Culture; Science; Strategy; Technology Adoption; Pharmaceutical Industry; Pharmaceutical Industry; United States; California; Puerto Rico; Rhode Island
- February 2021
- Case
Digital Manufacturing at Amgen
By: Shane Greenstein, Kyle R. Myers and Sarah Mehta
This case discusses efforts made by biotechnology (biotech) company Amgen to introduce digital technologies into its manufacturing processes. Doing so is complicated by the fact that the process for manufacturing biologics—or therapeutics made from living cells—is... View Details
Keywords: Digital Technologies; Change; Change Management; Decision Making; Cost vs Benefits; Decisions; Information; Analytics and Data Science; Innovation and Invention; Innovation and Management; Innovation Leadership; Innovation Strategy; Technological Innovation; Jobs and Positions; Knowledge; Leadership; Organizational Culture; Science; Strategy; Information Technology; Technology Adoption; Pharmaceutical Industry; Pharmaceutical Industry; United States; California; Puerto Rico; Rhode Island
Greenstein, Shane, Kyle R. Myers, and Sarah Mehta. "Digital Manufacturing at Amgen." Harvard Business School Case 621-008, February 2021.
- November 2020
- Supplement
Valuing Celgene's CVR
By: Benjamin C. Esty and Daniel Fisher
When Bristol-Myers Squibb (BMS) acquired Celgene Corporation in November 2019, Celgene shareholders received cash, BMS stock, and a contingent value right (CVRs) that would pay $9 if the U.S. Food and Drug Administration (FDA) approved three of Celgene’s late stage... View Details
- January 2018
- Teaching Note
BeiGene
By: Willy Shih and Jimmy Zhang
Teaching Note for HBS No. 618-033. View Details
- June 2014
- Supplement
Merrimack Pharmaceuticals, Inc. (B)
By: Amy C. Edmondson, Bethany Gerstein and Melissa Valentine
In 2006, the leadership team at Merrimack Pharmaceuticals, Inc. had to decide whether to keep its R&D organization in functional departments or restructure it into interdisciplinary teams. This case follows the outcomes of this decision from 2006 to mid-2014, and... View Details
Keywords: Organizational Design; Groups and Teams; Collaborative Innovation and Invention; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry
Edmondson, Amy C., Bethany Gerstein, and Melissa Valentine. "Merrimack Pharmaceuticals, Inc. (B)." Harvard Business School Supplement 614-083, June 2014.
- January 2014 (Revised June 2015)
- Teaching Note
Amgen Inc: Pursuing Innovation and Imitation? (A), (B)
By: Ian Mackenzie
- May 2013 (Revised October 2014)
- Case
Novartis: Leading a Global Enterprise
By: William W. George, Krishna G. Palepu and Carin-Isabel Knoop
Novartis, the world's leading healthcare company, was formed in 1996 out of a merger of two very different, mid-tier Switzerland-based pharma companies. The case traces the company's evolution over the past 17 years, as it transformed into a truly global enterprise... View Details
Keywords: Multinational Firms and Management; Talent and Talent Management; Organizational Structure; Organizational Culture; Success; Globalized Markets and Industries; Management Teams; Change Management; Business History; Mergers and Acquisitions; Global Strategy; Health Care and Treatment; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland
George, William W., Krishna G. Palepu, and Carin-Isabel Knoop. "Novartis: Leading a Global Enterprise." Harvard Business School Case 413-096, May 2013. (Revised October 2014.)
- February 2010 (Revised April 2010)
- Case
Organization and Strategy at Millennium (A)
By: Julie M. Wulf and Scott Waggoner
This case examines Millennium's strategic and organizational responses to the rapid evolution of the biopharmaceutical industry. In the early 2000s, as Millennium's competitive advantage in early-stage research slipped away and its losses mounted, founder and CEO Mark... View Details
Keywords: Transformation; Leading Change; Management Succession; Organizational Change and Adaptation; Competitive Strategy; Competitive Advantage; Pharmaceutical Industry; Pharmaceutical Industry
Wulf, Julie M., and Scott Waggoner. "Organization and Strategy at Millennium (A)." Harvard Business School Case 710-415, February 2010. (Revised April 2010.)
- January 2009
- Teaching Note
Biocon: Launching a New Cancer Drug in India (TN)
By: Sunil Gupta and Das Narayandas
Teaching Note for [508026]. View Details